Vascular Endothelial Growth Factor (VEGF) Inhibitor Market 2026 projected to reach $16.23 billion by 2030 at a CAGR of 7.6%
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market From 2026 To 2030?
The vascular endothelial growth factor (vegf) inhibitor market size has demonstrated substantial growth over recent years. It is projected to expand from $11.3 billion in 2025 to $12.11 billion in 2026, growing at a compound annual growth rate (CAGR) of 7.2%. The market’s expansion in the past can be attributed to a rising incidence of cancer and retinal disorders, limited treatment alternatives before monoclonal antibodies were available, increased awareness regarding the benefits of anti-angiogenic therapy, greater physician adoption of targeted therapies, and the regulatory approvals for first-generation vegf inhibitors.
The vascular endothelial growth factor (vegf) inhibitor market size is anticipated to demonstrate robust growth over the next few years, expanding to $16.23 billion by 2030 with a compound annual growth rate (CAGR) of 7.6%. This projected growth within the forecast period is attributable to the development of next-generation vegf inhibitors, the expansion of immuno-oncology combinations, increasing adoption of personalized medicine, rising investments in ophthalmic drug development, and the integration of digital monitoring and AI-based treatment assessment. Significant trends during the forecast period include the growing uptake of vegf inhibitors in oncology and ophthalmology, an increase in the development of monoclonal antibodies and anti-angiogenic therapies, the expansion of intravitreal and intravenous administration routes, a broader application of personalized medicine and targeted therapy approaches, and an increase in clinical trials and research for novel vegf inhibitors.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3437&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
The increasing incidence of cancer and macular degeneration is anticipated to drive the expansion of the VEGF inhibitor market in the future. Cancer is characterized by the uncontrolled proliferation of abnormal cells that may disseminate throughout the body, whereas macular degeneration is a medical ailment resulting in the degradation of the retina’s central area, impairing sight. The rising occurrence of these ailments is driven by factors like an aging demographic and lifestyle-associated dangers, thereby escalating the need for efficacious treatments and healthcare interventions. Vascular endothelial growth factor (VEGF) Inhibitors counter cancer by preventing the creation of new blood vessels essential for tumor development and dissemination, consequently curbing tumor proliferation and metastasis. For example, data from February 2024 by the World Health Organization, an international organization based in Switzerland focused on global health policy and public health endeavors, projects more than 35 million new cancer cases by 2050, representing a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the increasing occurrence of cancer and macular degeneration is propelling the expansion of the VEGF inhibitor market.
Which Segments Are Included In The Analysis Of The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
The vascular endothelial growth factor (vegf) inhibitor market covered in this report is segmented –
1) By Drugs Type: Avastin, Tecentriq, Lucentis, Cometriq, Eylea, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Intravitreal
3) By Application: Oncology, Ophthalmology, Other Applications
Subsegments:
1) By Avastin: Oncology Applications, Ophthalmology Applications
2) By Tecentriq: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Bladder Cancer, Triple-Negative Breast Cancer
3) By Lucentis: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Retinal Vein Occlusion
4) By Cometriq: Medullary Thyroid Cancer, Renal Cell Carcinoma
5) By Eylea: Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
6) By Other Drug Types: Immuno-Oncology Drugs, Anti-Angiogenic Agents, Other Monoclonal Antibodies
Which Trends Are Impacting The Growth Of The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
Leading companies in the VEGF inhibitor market are prioritizing the creation of innovative ophthalmic treatments, notably higher-concentration intravitreal injection solutions, to extend dosing intervals and alleviate the treatment burden for patients. These solutions are eye medications containing an elevated amount of active drug per dose, which helps reduce the frequency of injections while maintaining effectiveness and easing the overall treatment load for patients. For instance, in April 2024, Santen Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, in collaboration with Bayer Yakuhin, a Japan-based pharmaceutical and life sciences company, launched the Ophthalmic VEGF Inhibitor Eylea 8mg Solution for Intravitreal Injection 114.3 mg/mL. Such treatments are standard for conditions like age-related macular degeneration (nAMD) and diabetic macular edema (DME), which can lead to blindness. Eylea 8mg, featuring a higher concentration compared to its predecessor, offers an extended dosing interval of up to 16 weeks, thereby reducing the frequency of intravitreal injections while preserving efficacy and safety. This advancement aims to lessen the patient’s treatment burden and establish a new standard of care. The partnership is a strategic move designed to expand the reach and availability of this innovative ophthalmic treatment.
Which Key Industry Participants Are Active In The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
Major companies operating in the vascular endothelial growth factor (vegf) inhibitor market are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., AstraZeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr. Reddy’s Laboratories, Innovent Biologics, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Ipsen, Oxurion, Pharmstandard Group, Zentiva, Coherus BioSciences Inc., AVEO pharmaceuticals, Eisai Co. Ltd.
Read the full vascular endothelial growth factor (vegf) inhibitor market report here:
What Are The Leading Geographic Regions In The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market?
North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2025. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the vascular endothelial growth factor (vegf) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3437&type=smp
Browse Through More Reports Similar to the Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market 2026, By The Business Research Company
Podiatry Services Market 2026
https://www.thebusinessresearchcompany.com/report/podiatry-services-market
Diagnostic Equipment Market Report 2026
https://www.thebusinessresearchcompany.com/report/diagnostic-equipment-global-market-report
Peripheral Vascular Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
